Metastatic Prostate Cancer Proven by 18F-FCH PET/CT Staging Scan in Patient With Normal PSA but High PSA Doubling Time

2013 ◽  
Vol 38 (9) ◽  
pp. 739-740 ◽  
Author(s):  
Marina Hodolič ◽  
Anna Margherita Maffione ◽  
Jure Fettich ◽  
Borut Gubina ◽  
Marino Cimitan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Doubling Time ◽  
Psa Doubling Time ◽  
Pet Ct

Extent of disease in recurrent prostate cancer determined by [68Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score

2015 ◽  
Vol 43 (3) ◽  
pp. 397-403 ◽  
Author(s):  
Frederik A. Verburg ◽  
David Pfister ◽  
Axel Heidenreich ◽  
Andreas Vogg ◽  
Natascha I. Drude ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gleason Score ◽  
Doubling Time ◽  
Recurrent Prostate Cancer ◽  
Psa Doubling Time ◽  
Pet Ct ◽  
Extent Of Disease

PSA and PSA Kinetics as Predictors for 18F-Fluciclovine PET/CT Positivity in Biochemically Recurrent Prostate Cancer

2021 ◽  
pp. 1-8
Author(s):  
Fabio Crocerossa ◽  
Umberto Carbonara ◽  
Jayashree Parekh ◽  
Alfredo Urdaneta ◽  
Samuel Weprin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Sequential Analysis ◽  
Doubling Time ◽  
Alternative Hypothesis ◽  
Imaging Techniques ◽  
Psa Kinetics ◽  
Psa Doubling Time ◽  
Pet Ct ◽  
Wide Range ◽  
Psa Velocity

<b><i>Introduction:</i></b> <sup>18</sup>F-Fluciclovine PET/CT is one of the imaging techniques currently employed to restage prostate cancer (PCa). Due to the conflicting results reported in the literature, it is not yet known at what PSA threshold <sup>18</sup>F-fluciclovine PET/CT could reliably demonstrate the presence of recurring disease. We explored the association between <sup>18</sup>F-fluciclovine PET/CT positivity and prescan PSA, PSA doubling time, and PSA velocity in patients with biochemical recurrence (BCR) of PCa after curative-intent treatment. <b><i>Methods:</i></b> Data from 59 patients who underwent <sup>18</sup>F-fluciclovine PET/CT for BCR after radical prostatectomy or radiotherapy were retrieved from a single institution database. Patients already undergone salvage treatments at the time of PET/CT, with newly diagnosed PCa or with initial diagnosis of metastatic PCa were excluded. A 2-sided independent samples Bayesian <i>t</i> test and Bayesian Mann-Whitney U test were used to assess the association between PET/CT and prescan PSA, PSA doubling time, and PSA velocity. <b><i>Results:</i></b> Evidence for no difference between PET/CT-positive and -negative patients for log-transformed PSA was found (BF<sub>01</sub> 3.61, % error: 0.01). Robustness check and sequential analysis showed stability across a wide range of prior distribution specifications. The hypothesis of no difference in terms of PSA-dt and for PSA-vel between groups was found to be more likely compared to the alternative hypothesis (BF<sub>01</sub> of 3.44 and 3.48, respectively). <b><i>Conclusion:</i></b> PSA and PSA kinetics are unlikely to be associated with <sup>18</sup>F-fluciclovine PET/CT positivity in patients with BCR, and none of these serum biomarkers might be used as single predictors of PET/CT detection. Larger studies might be needed to evaluate the role of different predictors.

scholarly journals Preliminary Clinical Experience oftrans-1-Amino-3-(18)F-fluorocyclobutanecarboxylic Acid (anti-(18)F-FACBC) PET/CT Imaging in Prostate Cancer Patients

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Kalevi Kairemo ◽  
Nigora Rasulova ◽  
Kaarina Partanen ◽  
Timo Joensuu
Keyword(s):  
Prostate Cancer ◽  
Lymph Nodes ◽  
Clinical Experience ◽  
Negative Correlation ◽  
Doubling Time ◽  
Strong Positive Correlation ◽  
Regional Lymph Nodes ◽  
Psa Doubling Time ◽  
Focal Uptake ◽  
Pet Ct

Background.In this retrospective analysis we assessed the role of [18F]-FACBC-PET/CT in the prostatic cancer staging.Procedure.30 first [18F]-FACBC-PET/CT images of 26 patients (68.1 ± 5.8 years) were analyzed. PET/CT findings were compared with PSA concentrations, with PSA doubling times (PDT), and with correlative imaging.Results.On 16 [18F]-FACBC (53.3%) scans, 58 metabolically active lesions were found. 12 (20.7%) lesions corresponding to the local relapse were found in prostate/prostate bed and seminal vesicles, 9 (15.5%) lesions were located in regional lymph nodes, 10 (17.2%) were located in distal lymph nodes, and 26 (44.8%) metabolically active lesions were found in the skeleton. In one case, focal uptake was found in the brain, confirmed further on MRI as meningioma. The mean S-PSA level in patients with positive [18F]-FACBC findings was 9.5 ± 16.9 μg/L (0.54–69 μg/L) and in patients with negative [18F]-FACBC findings was 1.96 ± 1.87 μg/L (0.11–5.9 μg/L), but the difference was not statistically significant. However, the PSA doubling time (PDT) in patients with positive findings was significantly shorter than PDT in patients with negative findings: 3.25 ± 2.09 months (0.3–6 months) versus 31.2 ± 22.02 months (8–84 months),P<0.0001. There was a strong positive correlation between PSA value and number of metabolically active lesions (R=0.74) and a negative correlation between PDT and number of metabolically active lesions (R=-0.56). There was a weak negative correlation between PDT andSUVmax⁡(R=-0.30).Conclusion.According to our preliminary clinical experience, [18F]-FACBC-PET may play a role inin vivorestaging of an active prostate cancer, especially in patients with a short S-PSA doubling time.

PSA HALF LIFE AND PSA DOUBLING TIME AS A PREDICTOR OF RESPONSE TO ANDROGEN DEPRIVATION THERAPY FOR METASTATIC PROSTATE CANCER

2008 ◽  
Vol 179 (4S) ◽  
pp. 185-185 ◽  
Author(s):  
Yong Hyun Park ◽  
Dong Soo Park ◽  
Chang Wook Jeong ◽  
Ja Hyun Ku ◽  
Cheol Kwak ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Half Life ◽  
Metastatic Prostate Cancer ◽  
Doubling Time ◽  
Androgen Deprivation ◽  
Psa Doubling Time

PSA doubling time for prediction of [11C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy

2010 ◽  
Vol 37 (6) ◽  
pp. 1106-1116 ◽  
Author(s):  
Giampiero Giovacchini ◽  
Maria Picchio ◽  
Vincenzo Scattoni ◽  
Rita Garcia Parra ◽  
Alberto Briganti ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Cancer Patients ◽  
Doubling Time ◽  
Biochemical Failure ◽  
Choline Pet ◽  
Psa Doubling Time ◽  
Ct Findings ◽  
Pet Ct

665: Baseline PSA and PSA Doubling Time Predict the Risk of Objective Progression and Death in Patients with T0-4 N0-2 M0 Prostate Cancer on Watchful Waiting

2006 ◽  
Vol 175 (4S) ◽  
pp. 215-215 ◽  
Author(s):  
Urs E. Studer ◽  
Laurence Collette ◽  
Peter Whelan ◽  
Walter Albrecht ◽  
Jacques Casselman ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Doubling Time ◽  
Watchful Waiting ◽  
Psa Doubling Time ◽  
Baseline Psa

scholarly journals [68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Jonathan Kuten ◽  
David Sarid ◽  
Ofer Yossepowitch ◽  
Nicola J. Mabjeesh ◽  
Einat Even-Sapir
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Added Value ◽  
Response To Treatment ◽  
Pet Ct ◽  
Monitoring Response

68Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy

2021 ◽  
pp. jnumed.121.263006
Author(s):  
Qaid Ahmed Shagera ◽  
Carlos Artigas ◽  
Ioannis Karfis ◽  
Gabriela Critchi ◽  
Nieves Martinez Chanza ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Metastatic Prostate Cancer ◽  
Outcome Prediction ◽  
Response Assessment ◽  
Psma Pet ◽  
Pet Ct

scholarly journals Resolution of the Expert Council on the New Approach to Drug Therapy for Non-Metastatic Castration-Resistant Prostate Cancer

2021 ◽  
Vol 59 (1) ◽  
pp. 8-11
Author(s):  
Dilyara Kaidarova ◽  
Oxana Shatkovskaya ◽  
Zaure Dushimova ◽  
Bakytzhan Ongarbayev
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Treatment Efficacy ◽  
Doubling Time ◽  
Distant Metastases ◽  
Diagnostic Methods ◽  
Efficacy And Safety ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Psa Doubling Time

Relevance: Prostate cancer (PC) is one of the most common malignant neoplasms in the male population. The widespread introduction of modern diagnostic methods and the determination of prostate-specific antigen (PSA) levels have increased the number of detected cases of localized and locally advanced PC forms. However, in some patients treated with radical methods and long-term androgen deprivation therapy (ADT), the disease continues to progress in the form of an increase in PSA levels with castration testosterone values and with no distant metastases. Such a course of the disease is referred to as non-metastatic castration-resistant prostate cancer (nmCRPC). Purpose: The article reports the results of a meeting of the Expert Council arranged by the Kazakh Research Institute of Oncology and Radiology on December 25, 2020, on non-metastatic castration-resistant prostate cancer diagnostics and treatment. Results: Large clinical studies highlight the critical importance of controlling the PSA doubling time as the main prognostic factor for an unfavorable outcome to increase patient survival and prevent the development of distant metastases. Based on the results of large randomized studies, experts recommended using new-generation androgen receptor antagonists in combination with ongoing ADT to improve the clinical outcomes in nmCRPC patients at high risk of metastatic progression. The Expert Council was presented with the data of a registration clinical study on darolutamide efficacy and safety. The advantages of introducing this drug into clinical practice to expand the choice of therapeutic options were identified. Personalized adjustment of a treatment regimen will increase the treatment efficacy and ensure higher survival in this category of patients. Conclusion: Increasing survival as the main objective in treating nmCRPC patients requires improved diagnostics through regular controlling of testosterone and PSA levels, calculation of PSA doubling time, and the use of radiological diagnostic methods to rule out distant metastases. The choice of therapy in patients at high risk of metastasis shall consider the patient’s status and the treatment efficacy and safety balance.

Sign in / Sign up

Export Citation Format

Share Document